NOVOLOG FLEXPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLOG FLEXPEN (NOVOLOG FLEXPEN).
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
| Metabolism | Degraded by insulin-degrading enzyme (IDE); metabolized into inactive metabolites. |
| Excretion | Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%) |
| Half-life | Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life |
| Protein binding | Weak (~10%) binding to plasma proteins, primarily albumin (no specific binding proteins reported) |
| Volume of Distribution | 0.3-0.4 L/kg (approximates extracellular fluid volume; not extensively distributed into tissues) |
| Bioavailability | Subcutaneous: 60-75% (absorbed rapidly from injection site) |
| Onset of Action | Subcutaneous: 10-20 minutes |
| Duration of Action | Subcutaneous: 3-5 hours (range 2-6 hours, dose-dependent); longer in patients with renal impairment |
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: no adjustment; GFR 15-29 mL/min: reduce dose by 25%; GFR <15 mL/min: reduce dose by 50%. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50%. |
| Pediatric use | Children aged 2-17 years: initial total daily dose 0.5-1.0 units/kg/day divided into multiple preprandial doses; dose titration based on glycemic response. |
| Geriatric use | Initiate at lower doses (e.g., 0.3-0.5 units/kg/day) to avoid hypoglycemia; more conservative titration and closer monitoring of renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLOG FLEXPEN (NOVOLOG FLEXPEN).
| Breastfeeding | Insulin aspart is excreted in breast milk in negligible amounts. M/P ratio not reported. Unlikely to affect infant glucose. Compatible with breastfeeding. Monitor infant for signs of hypoglycemia. |
| Teratogenic Risk | Insulin aspart (Novolog) does not cross the placenta at therapeutic doses. No increased risk of major congenital anomalies has been observed. Poor glycemic control increases risks of miscarriage, congenital anomalies (first trimester), macrosomia, neonatal hypoglycemia, respiratory distress, and polyhydramnios (second and third trimesters). |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to insulin aspart or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia","Hypokalemia","Risk of medication errors due to product confusion","Not for use in insulin infusion pumps or intravenous administration"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose (fasting, postprandial, HbA1c) and ketones. Fetal surveillance: ultrasound for anatomy, growth, and amniotic fluid index; nonstress test and biophysical profile in third trimester. Monitor for maternal hypoglycemia and diabetic ketoacidosis. |
| Fertility Effects | No direct effect on fertility. Improved glycemic control can restore fertility in women with diabetes-related menstrual irregularities. |